Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407940 | 0.90 | TSHR (0.50) | LTA4HTACR1CYP2D6SIGMAR1TSHR | |
| SCHEMBL5562683 | 0.88 | LTA4H (0.49) | LTA4HTACR1CYP2D6SIGMAR1TSHR | |
| SCHEMBL5562676 | 0.88 | LTA4H (0.49) | LTA4HTACR1CYP2D6SIGMAR1TSHR | |
| SCHEMBL3491795 | 0.82 | LTA4H (0.61) | LTA4HTACR1CYP2D6SIGMAR1ACHE | |
| SCHEMBL18325 | 0.82 | LTA4H (0.61) | LTA4HTACR1CYP2D6SIGMAR1ACHE | |
| SCHEMBL24350 | 0.82 | LTA4H (0.61) | LTA4HTACR1CYP2D6SIGMAR1ACHE | |
| SCHEMBL4287182 | 0.82 | LTA4H (0.53) | LTA4HTACR1CYP2D6SIGMAR1ACHE | |
| SCHEMBL4282463 | 0.82 | LTA4H (0.53) | LTA4HTACR1CYP2D6SIGMAR1ACHE | |
| SCHEMBL4288685 | 0.81 | LTA4H (0.52) | LTA4HTACR1CYP2D6SIGMAR1 | |
| SCHEMBL7826925 | 0.81 | TACR1 (0.74) | LTA4HTACR1CYP2D6SIGMAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0873320-B1 | PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
| US-6087357-A | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| CN-1209125-A | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-02-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | PKD2, SSTR5, TAC3 | LTA4H 754/4885TACR1 5/4885CYP2D6 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.